Highly specific and sensitive reagents for antibody drug development assays.
Technical articles featuring applications of anti-idiotypic antibodies.
Ready-made recombinant monoclonal anti-idiotypic antibodies, highly specific for the humanized antibody drug palivizumab (Synagis®).
The Type 1 anti-palivizumab antibodies inhibit the binding of the drug palivizumab to its target, a highly conserved region on the F protein of respiratory syncytial virus (RSV), and therefore detect free drug. These antibodies are ideal for use in indirect ELISA, to develop pharmacokinetic (PK) bridging assays and as a reference standard for anti-drug antibody (ADA) assays.
These recombinant monoclonal antibodies are generated using the HuCAL® antibody library and an improved proprietary method of phage display, which results in highly specific and sensitive reagents. These are ideal for PK and PD assays. Antibodies are fully human, so they are also perfect as controls or calibrators for ADA assays. The in vitro production of recombinant antibodies means that there is a consistent, secure supply throughout preclinical development and clinical trials, avoiding the need to develop new reagents.
More information about anti-idiotypic antibodies and their binding types and properties
|Product Code||Clone||Antibody Specificity||Binding Type||Format||Affinity KD, nM||Assay Development Recommendations|
PK bridging ELISA as capture and detection antibody
PK bridging ELISA with HCA262
|HCA262||AbD23967_hIgG1||Palivizumab||Type 1||Human IgG1||1.5*||
PK bridging ELISA with HCA261
PK bridging ELISA with HCA261
Table 1 Antibody Specifications
*Affinity measured in the monovalent Fab form
Schematic image of PK Bridging ELISA. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Ig format (blue), labeled with HRP
Figure 1: Palivizumab PK ELISA bridging format using antibodies HCA261 and HCA262
Figure 1: Anti-palivizumab antibody, clone AbD23967 (HCA261) was coated on a microtiter plate at 1.0 µg/ml and left over night. Washing and blocking was performed with PBST + 5% BSA. 10% human serum was added and spiked with increasing concentrations of palivizumab. Detection was performed using HRP conjugated anti-palivizumab antibody clone AbD23967_hIgG1 (HCA262P) diluted to 2 µg/ml in HISPEC buffer (BUF049A), plus QuantaBlu™ fluorogenic peroxidase substrate. Data are shown as the mean of three measurements.
Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue)
Figure 2: ADA assay, bridging format using antibody HCA262
Figure 2: Palivizumab was coated at 0.5 µg/ml on a microtiter plate overnight. After washing and blocking with PBST + 5% BSA, PBST with 10% human serum was added spiked with increasing concentrations of the human anti-palivizumab antibody clone AbD23967_hIgG1 (HCA262). Detection was performed using HRP conjugated palivizumab at 2 µg/ml in HISPEC assay diluent and QuantaBlu fluorogenic peroxidase substrate. Data are shown as the mean of three measurements. HRP conjugation of palivizumab was performed using a LYNX Rapid HRP Antibody Conjugation Kit®.
Figure 3: Demonstration of the specificity of antibody HCA261 to palivizumab
Figure 3: A microtiter plate was coated over night with various antigens at a concentration of 5 µg/ml. After washing and blocking with PBST + 5% BSA, detection was performed using anti-palivizumab antibody (clone AbD23967, HCA261) at a concentration of 2 µg/ml followed by an HRP labeled anti-DYKDDDDK tag antibody in HISPEC diluent and QuantaBlu fluorogenic peroxidase substrate.
Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
HuCAL® is a registered trademark of MorphoSys AG. QuantaBlu™ is a trademark of Thermo FisherScientific. Synagis® is a registered trademark of the AstraZeneca group of companies.